Skip to main content
Top
Published in: International Urology and Nephrology 3/2010

01-09-2010 | Nephrology – Translational Section

High mobility group box protein-1 crossing cell borders may incite an inflammatory “tornado” in renal disease

Authors: V. Shpacovitch, P. R. Mertens

Published in: International Urology and Nephrology | Issue 3/2010

Login to get access

Excerpt

High mobility group box 1 (HMGB-1) protein has been widely studied as a DNA-binding nuclear protein that regulates gene transcription, maintains nucleosome structure and modulates the activity of steroid hormone receptors [1]. Besides these classical functions as transcription factor, HMGB-1 may also be released by the cells into the extracellular milieu. This release process may be clearly distinguished from a passive process occurring with profound cell damage, e.g., necrosis or apoptosis, and has been elucidated as an active process in monocytes and macrophages after pro-inflammatory stimulation with LPS, IFN-γ, TNFα or IL-1β. “Outside” cells, HMGB-1 serves as an inflammatory mediator affecting synthesis of TNFα, monocyte chemotactic protein (MCP)-1 and expression of cell adhesion molecules ICAM-1 and VCAM-1 [2]. A recent publication by Oyama et al. [3] sheds light on the potent role of HMGB-1 in an experimental nephritis model caused by adenine excess. …
Literature
1.
go back to reference Landsman D, Bustin M (1993) A signature for the HMG-1 box DNA-binding proteins. Bioessays 15(8):539–546CrossRefPubMed Landsman D, Bustin M (1993) A signature for the HMG-1 box DNA-binding proteins. Bioessays 15(8):539–546CrossRefPubMed
2.
go back to reference Sims GP, Rowe DC, Rietdijk ST et al (2010) HMGB1 and RAGE in inflammation and cancer. Annual Rev Immunol 28:367–388CrossRef Sims GP, Rowe DC, Rietdijk ST et al (2010) HMGB1 and RAGE in inflammation and cancer. Annual Rev Immunol 28:367–388CrossRef
3.
go back to reference Oyama Y, Hashiguchi T, Taniguchi N et al (2010) High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy. Lab Invest 90(6):853–866CrossRefPubMed Oyama Y, Hashiguchi T, Taniguchi N et al (2010) High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy. Lab Invest 90(6):853–866CrossRefPubMed
4.
go back to reference Rendon-Mitchell B, Ochani M, Li J et al (2003) IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 170(7):3890–3897PubMed Rendon-Mitchell B, Ochani M, Li J et al (2003) IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 170(7):3890–3897PubMed
5.
go back to reference Wang H, Bloom O, Zhang M et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285(5425):248–251CrossRefPubMed Wang H, Bloom O, Zhang M et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285(5425):248–251CrossRefPubMed
6.
7.
go back to reference Mantell LL, Parrish WR, Ulloa L (2006) Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Shock 25(1):4–11CrossRefPubMed Mantell LL, Parrish WR, Ulloa L (2006) Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Shock 25(1):4–11CrossRefPubMed
8.
go back to reference Li J, Xie H, Wen T et al (2010) Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J Rheumatol 37(4):766–775CrossRefPubMed Li J, Xie H, Wen T et al (2010) Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J Rheumatol 37(4):766–775CrossRefPubMed
9.
go back to reference Yan XX, Lu L, Peng WH et al (2009) Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 205(2):544–548CrossRefPubMed Yan XX, Lu L, Peng WH et al (2009) Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 205(2):544–548CrossRefPubMed
10.
go back to reference Yang H, Ochani M, Li J et al (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 101(1):296–301CrossRefPubMed Yang H, Ochani M, Li J et al (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 101(1):296–301CrossRefPubMed
11.
go back to reference Kaczorowski DJ, Tsung A, Billiar TR (2009) Innate immune mechanisms in ischemia/reperfusion. Front Biosci 1:91–98 Kaczorowski DJ, Tsung A, Billiar TR (2009) Innate immune mechanisms in ischemia/reperfusion. Front Biosci 1:91–98
12.
go back to reference D’Agati V, Schmidt AM (2010) RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol 6(6):352–360CrossRefPubMed D’Agati V, Schmidt AM (2010) RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol 6(6):352–360CrossRefPubMed
13.
go back to reference Chen G, Ward MF, Sama AE et al (2004) Extracellular HMGB1 as a proinflammatory cytokine. J Interferon Cytokine Res 24(6):329–333CrossRefPubMed Chen G, Ward MF, Sama AE et al (2004) Extracellular HMGB1 as a proinflammatory cytokine. J Interferon Cytokine Res 24(6):329–333CrossRefPubMed
14.
go back to reference Zhao J, Tramontano A, Makker SP (2007) Albumin-stimulated TGFbeta-1 in renal tubular cells is associated with activation of MAP kinase. Int Urol Nephrol 39(4):1265–1271CrossRefPubMed Zhao J, Tramontano A, Makker SP (2007) Albumin-stimulated TGFbeta-1 in renal tubular cells is associated with activation of MAP kinase. Int Urol Nephrol 39(4):1265–1271CrossRefPubMed
15.
go back to reference Fiuza C, Bustin M, Talwar S et al (2003) Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101(7):2652–2660CrossRefPubMed Fiuza C, Bustin M, Talwar S et al (2003) Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101(7):2652–2660CrossRefPubMed
16.
go back to reference Oh YJ, Youn JH, Ji Y et al (2009) HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J Immunol 182(9):5800–5809CrossRefPubMed Oh YJ, Youn JH, Ji Y et al (2009) HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J Immunol 182(9):5800–5809CrossRefPubMed
17.
go back to reference Hruby Z, Kopec W, Szewczyk Z (1985) Activity of circulating monocytes in patients with chronic glomerulonephritis. Int Urol Nephrol 17(4):379–387CrossRefPubMed Hruby Z, Kopec W, Szewczyk Z (1985) Activity of circulating monocytes in patients with chronic glomerulonephritis. Int Urol Nephrol 17(4):379–387CrossRefPubMed
18.
go back to reference Hruby Z, Lowry RP, Forbes RD et al (1988) Immune mechanisms and molecular mediators of glomerular injury in experimental nephritis. Summary of current results and continuing studies. Int Urol Nephrol 20(5):513–517CrossRefPubMed Hruby Z, Lowry RP, Forbes RD et al (1988) Immune mechanisms and molecular mediators of glomerular injury in experimental nephritis. Summary of current results and continuing studies. Int Urol Nephrol 20(5):513–517CrossRefPubMed
19.
go back to reference Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391(6662):82–86CrossRefPubMed Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391(6662):82–86CrossRefPubMed
20.
go back to reference Lee JH, Woo JH, Woo SU et al (2008) The 15-deoxy-delta 12, 14-prostaglandin J2 suppresses monocyte chemoattractant protein-1 expression in IFN-gamma-stimulated astrocytes through induction of MAPK phosphatase-1. J Immunol 181(12):8642–8649PubMed Lee JH, Woo JH, Woo SU et al (2008) The 15-deoxy-delta 12, 14-prostaglandin J2 suppresses monocyte chemoattractant protein-1 expression in IFN-gamma-stimulated astrocytes through induction of MAPK phosphatase-1. J Immunol 181(12):8642–8649PubMed
Metadata
Title
High mobility group box protein-1 crossing cell borders may incite an inflammatory “tornado” in renal disease
Authors
V. Shpacovitch
P. R. Mertens
Publication date
01-09-2010
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 3/2010
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-010-9829-1

Other articles of this Issue 3/2010

International Urology and Nephrology 3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.